COMPARISON OF NETWORK META-ANALYSIS METHODOLOGIES USED TO ASSESS FIRST-LINE TREATMENTS IN RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW

被引：0
|
作者：
Marciniak, A. [1 ]
Orbzut, G. [2 ]
Dlotko, E. [2 ]
Fu, S. [3 ]
Mollon, P. [1 ]
Wallace, J. F. [4 ]
机构：
[1] Ipsen, Boulogne, France
[2] Certara, Krakow, Poland
[3] Certara, Lorrach, BW, Germany
[4] Exelixis Inc, Alameda, CA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
SA8
引用
收藏
页码：S605 / S606
页数：2
相关论文
共 50 条
  • [31] Efficacy of First-Line CLL Treatments in Comparison to Chlorambucil: A Network Meta-Analysis
    Firwana, Belal
    Sonbol, Mohamad Bassam
    Atrash, Shebli
    Ravilla, Rahul
    Raval, Mihir
    Hao, Lin
    Jethava, Yogesh
    Veeraputhiran, Muthu
    Makhoul, Issam
    Sasapu, Appalanaidu
    BLOOD, 2016, 128 (22)
  • [32] Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: A systematic review and meta-analysis
    Kim, Jinchul
    Cho, Jinhyun
    Byeon, Seonggyu
    Kim, Won Seog
    Kim, Seok Jin
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (05) : 664 - 673
  • [33] Optimal First-Line Treatment of Metastatic Renal-Cell Carcinoma: A Network Meta-Analysis
    Hahn, Andrew W.
    Hale, Peter
    Maughan, Benjamin L.
    Haaland, Benjamin
    Agarwal, Neeraj
    KIDNEY CANCER, 2018, 2 (02) : 115 - 121
  • [34] Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
    Kirsi M. Manz
    Klaus Fenchel
    Andreas Eilers
    Jonathan Morgan
    Kirsten Wittling
    Wolfram C. M. Dempke
    Advances in Therapy, 2020, 37 : 730 - 744
  • [35] Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
    Manz, Kirsi M.
    Fenchel, Klaus
    Eilers, Andreas
    Morgan, Jonathan
    Wittling, Kirsten
    Dempke, Wolfram C. M.
    ADVANCES IN THERAPY, 2020, 37 (02) : 730 - 744
  • [36] Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma
    Climent, Miguel A.
    Munoz-Langa, Jose
    Basterretxea-Badiola, Laura
    Santander-Lobera, Carmen
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 121 : 45 - 50
  • [37] First-Line Immunotherapy Combinations in Advanced Renal Cell Carcinoma: A Rapid Review and Meta-Analysis
    Shpilsky, Jason
    Catalano, Paul J.
    McDermott, David F.
    KIDNEY CANCER, 2021, 5 (03) : 153 - 163
  • [38] Systematic review and network meta-analysis of first line treatments in mRCC.
    Ratto, Barbara Elizabeth
    Chakraborty, Sutirtha
    Chinthapatla, Harini
    Kalra, Manik
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis
    Elaidi, Reza
    Phan, Letuan
    Borchiellini, Delphine
    Barthelemy, Philippe
    Ravaud, Alain
    Oudard, Stephane
    Vano, Yann
    CANCERS, 2020, 12 (06) : 1 - 13
  • [40] Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis
    Quhal, Fahad
    Mori, Keiichiro
    Fajkovic, Harun
    Remzi, Mesut
    Shariat, Shahrokh F.
    Schmidinger, Manuela
    CURRENT OPINION IN UROLOGY, 2022, 32 (01) : 61 - 68
12345